董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Filderman | -- | Director | -- | 未披露 | 未持股 | 2026-01-07 |
| Melissa Leonard | -- | Director | -- | 未披露 | 未持股 | 2026-01-07 |
| Dalton Smart | -- | Director | -- | 未披露 | 未持股 | 2026-01-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shane Ward | 男 | Chief Operating Officer, Chief Legal Officer and Corporate Secretary | 50 | 未披露 | 未持股 | 2026-01-07 |
| Frank Karbe | 男 | Chief Financial Officer | 57 | 未披露 | 未持股 | 2026-01-07 |
| Jeffrey Stein | 男 | President and Chief Executive Officer | 71 | 182.38万美元 | 未持股 | 2026-01-07 |
董事简历
中英对照 | 中文 | 英文- Jon Filderman
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Melissa Leonard
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Dalton Smart
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Shane Ward
Shane Ward，曾是一名独立的生物技术顾问。2018年5月至2021年12月，他在当时上市的生物制药公司Bellicum制药公司担任首席法律和战略官。在其职业生涯的早期，Ward先生是商业制药公司吉利德科学、雅培和人类基因组科学公司的高级内部律师。他的法律生涯始于国际律师事务所Sidley Austin LLP的合伙人。Ward先生拥有弗吉尼亚大学的学士学位、乔治敦大学法律中心的法学博士学位、女王大学（加拿大）史密斯商学院的工商管理硕士学位和康奈尔大学庄臣管理研究生院的工商管理硕士学位。
Shane Ward,was an independent biotechnology consultant. From May 2018 to December 2021, he served as the Chief Legal and Strategy Officer for Bellicum Pharmaceuticals, Inc., a then-publicly-traded biopharmaceutical company. Earlier in his career, Mr. Ward was a senior in-house attorney with commercial pharmaceutical companies Gilead Sciences, Abbott Laboratories and Human Genome Sciences. He began his legal career as an associate for the international law firm Sidley Austin LLP. Mr. Ward holds a B.A. from the University of Virginia, a J.D. from Georgetown University Law Center, an M.B.A. from the Smith School of Business, Queen's University (Canada) and an M.B.A. from the SC Johnson Graduate School of Management, Cornell University.- Shane Ward，曾是一名独立的生物技术顾问。2018年5月至2021年12月，他在当时上市的生物制药公司Bellicum制药公司担任首席法律和战略官。在其职业生涯的早期，Ward先生是商业制药公司吉利德科学、雅培和人类基因组科学公司的高级内部律师。他的法律生涯始于国际律师事务所Sidley Austin LLP的合伙人。Ward先生拥有弗吉尼亚大学的学士学位、乔治敦大学法律中心的法学博士学位、女王大学（加拿大）史密斯商学院的工商管理硕士学位和康奈尔大学庄臣管理研究生院的工商管理硕士学位。
- Shane Ward,was an independent biotechnology consultant. From May 2018 to December 2021, he served as the Chief Legal and Strategy Officer for Bellicum Pharmaceuticals, Inc., a then-publicly-traded biopharmaceutical company. Earlier in his career, Mr. Ward was a senior in-house attorney with commercial pharmaceutical companies Gilead Sciences, Abbott Laboratories and Human Genome Sciences. He began his legal career as an associate for the international law firm Sidley Austin LLP. Mr. Ward holds a B.A. from the University of Virginia, a J.D. from Georgetown University Law Center, an M.B.A. from the Smith School of Business, Queen's University (Canada) and an M.B.A. from the SC Johnson Graduate School of Management, Cornell University.
- Frank Karbe
Frank Karbe自2016年9月起担任本社首席财务会计官。Karbe先生于2017年4月被任命为Myovant Sciences, Inc.的首席财务官，随后于2020年2月被任命为总裁兼首席财务官。从2014年9月到2016年7月，Karbe先生担任全球大众参与活动平台The Color Run的总裁，负责领导运营和财务职能。2004年1月至2014年6月，Karbe先生在生物技术公司Exelixis, Inc.担任执行副总裁兼首席财务官。Karbe先生在Exelixis任职期间，负责领导财务组织、内外部沟通、业务发展、信息技术、公司战略及其他各项运营职能。在2004年加入Exelixis之前，Karbe先生曾在Goldman Sachs & Co.担任投资银行家，最近担任医疗保健集团副总裁，为客户提供公司融资和并购方面的建议。在1997年加入Goldman Sachs之前，Karbe先生曾在欧洲Royal Dutch/Shell Group的财务部门担任多个职务。Karbe先生于2019年4月至2020年10月Aduro Biotech，Inc.与Chinook Therapeutics, Inc.合并期间担任Aduro Biotech, Inc.的董事。Karbe先生还于2010年至2018年担任Arbutus Biopharma Corporation的董事。Karbe先生获得了德国科布伦茨WHU-Otto Beisheim管理研究生院颁发的Diplom-Kaufmann。
Frank Karbe has served as our Principal Financial and Accounting Officer since September 2016. Mr. Karbe was appointed as Myovant Sciences, Inc.'s Chief Financial Officer in April 2017 and was subsequently appointed as President and Chief Financial Officer in February 2020. From September 2014 to July 2016 Mr. Karbe served as President of The Color Run, a global mass participation events platform, where he was responsible for leading the operational and financial functions. From January 2004 to June 2014 Mr. Karbe was the Executive Vice President and Chief Financial Officer of Exelixis, Inc., a biotechnology company. During his tenure at Exelixis, Mr. Karbe was responsible for leading the finance organization, internal and external communications, business development, information technology, corporate strategy and various other operational functions. Prior to joining Exelixis in 2004 Mr. Karbe worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group advising clients on corporate finance and mergers and acquisitions. Prior to joining Goldman Sachs in 1997 Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. Mr. Karbe served as a director of Aduro Biotech, Inc. from April 2019 to October 2020 when Aduro Biotech was merged with Chinook Therapeutics, Inc. Mr. Karbe also served as a director of Arbutus Biopharma Corporation from 2010 to 2018. Mr. Karbe received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.- Frank Karbe自2016年9月起担任本社首席财务会计官。Karbe先生于2017年4月被任命为Myovant Sciences, Inc.的首席财务官，随后于2020年2月被任命为总裁兼首席财务官。从2014年9月到2016年7月，Karbe先生担任全球大众参与活动平台The Color Run的总裁，负责领导运营和财务职能。2004年1月至2014年6月，Karbe先生在生物技术公司Exelixis, Inc.担任执行副总裁兼首席财务官。Karbe先生在Exelixis任职期间，负责领导财务组织、内外部沟通、业务发展、信息技术、公司战略及其他各项运营职能。在2004年加入Exelixis之前，Karbe先生曾在Goldman Sachs & Co.担任投资银行家，最近担任医疗保健集团副总裁，为客户提供公司融资和并购方面的建议。在1997年加入Goldman Sachs之前，Karbe先生曾在欧洲Royal Dutch/Shell Group的财务部门担任多个职务。Karbe先生于2019年4月至2020年10月Aduro Biotech，Inc.与Chinook Therapeutics, Inc.合并期间担任Aduro Biotech, Inc.的董事。Karbe先生还于2010年至2018年担任Arbutus Biopharma Corporation的董事。Karbe先生获得了德国科布伦茨WHU-Otto Beisheim管理研究生院颁发的Diplom-Kaufmann。
- Frank Karbe has served as our Principal Financial and Accounting Officer since September 2016. Mr. Karbe was appointed as Myovant Sciences, Inc.'s Chief Financial Officer in April 2017 and was subsequently appointed as President and Chief Financial Officer in February 2020. From September 2014 to July 2016 Mr. Karbe served as President of The Color Run, a global mass participation events platform, where he was responsible for leading the operational and financial functions. From January 2004 to June 2014 Mr. Karbe was the Executive Vice President and Chief Financial Officer of Exelixis, Inc., a biotechnology company. During his tenure at Exelixis, Mr. Karbe was responsible for leading the finance organization, internal and external communications, business development, information technology, corporate strategy and various other operational functions. Prior to joining Exelixis in 2004 Mr. Karbe worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group advising clients on corporate finance and mergers and acquisitions. Prior to joining Goldman Sachs in 1997 Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. Mr. Karbe served as a director of Aduro Biotech, Inc. from April 2019 to October 2020 when Aduro Biotech was merged with Chinook Therapeutics, Inc. Mr. Karbe also served as a director of Arbutus Biopharma Corporation from 2010 to 2018. Mr. Karbe received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.
- Jeffrey Stein
Jeffrey Stein，自2014年10月起在Paratek Pharmaceuticals, Inc.董事会任职，并于2022年12月被任命为Paratek Pharmaceuticals, Inc.首席独立董事。Stein博士自2014年起担任Cidara Therapeutics, Inc.（Cidara）的总裁、首席执行官兼董事。在加入Cidara之前，Stein博士是Trius Therapeutics，Inc.的首席执行官，从2007年创立到2013年9月被Cubist Pharmaceuticals收购。Stein博士也是抗生素工作组的创始主席和总裁，该工作组是行业领先的501（c）（6）组织。除了在Cidara和Paratek的董事会任职外，Stein博士目前还是Ideaya Biosciences，Inc.的董事，并在圣地亚哥Life Science Cares的管理委员会任职。此前，Stein博士是Sofinnova Ventures的风险合伙人和Kauffman研究员，并于2005年开设了该公司的圣地亚哥办事处。在加入Sofinnova Ventures之前，Stein博士是Quorex Pharmaceuticals，Inc.的联合创始人兼首席科学官，该公司于2005年被辉瑞制药公司收购。他还曾在Diversa公司和Agouron研究所担任首席科学家。Stein博士在加州理工学院作为Alexander Hollaender杰出博士后研究员开展了博士后研究，并在加州大学圣地亚哥分校作为NASA研究生研究员开展了研究生工作。
Jeffrey Stein,was Chief Executive Officer of Trius Therapeutics, Inc., from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.- Jeffrey Stein，自2014年10月起在Paratek Pharmaceuticals, Inc.董事会任职，并于2022年12月被任命为Paratek Pharmaceuticals, Inc.首席独立董事。Stein博士自2014年起担任Cidara Therapeutics, Inc.（Cidara）的总裁、首席执行官兼董事。在加入Cidara之前，Stein博士是Trius Therapeutics，Inc.的首席执行官，从2007年创立到2013年9月被Cubist Pharmaceuticals收购。Stein博士也是抗生素工作组的创始主席和总裁，该工作组是行业领先的501（c）（6）组织。除了在Cidara和Paratek的董事会任职外，Stein博士目前还是Ideaya Biosciences，Inc.的董事，并在圣地亚哥Life Science Cares的管理委员会任职。此前，Stein博士是Sofinnova Ventures的风险合伙人和Kauffman研究员，并于2005年开设了该公司的圣地亚哥办事处。在加入Sofinnova Ventures之前，Stein博士是Quorex Pharmaceuticals，Inc.的联合创始人兼首席科学官，该公司于2005年被辉瑞制药公司收购。他还曾在Diversa公司和Agouron研究所担任首席科学家。Stein博士在加州理工学院作为Alexander Hollaender杰出博士后研究员开展了博士后研究，并在加州大学圣地亚哥分校作为NASA研究生研究员开展了研究生工作。
- Jeffrey Stein,was Chief Executive Officer of Trius Therapeutics, Inc., from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.